Bayer puts new production plant into operation
The pharmaceutical company Bayer has commissioned a new production facility at its Berlin site at an investment cost of 130 million euros. The centerpiece is an automated and robot-controlled filling system. According to the listed company, the underlying technology sets standards in the production of liquid medicines such as injection and infusion solutions. In future, the plant will be used to produce medicines for areas with high medical demand, such as ophthalmology or oncology, for markets in the USA, Europe and China.
Stefan Oelrich, Head of the Pharmaceuticals Division, described it as an "intelligent combination of new technologies". The highly digitalized production process enables fast and sterile work. "It's great to see a German company like Bayer AG driving innovation in Berlin," said Berlin's Governing Mayor, Kai Wegner (CDU), at the commissioning of the facility on Thursday at Bayer's global pharmaceutical headquarters in Berlin-Mitte.
The project is part of a billion-euro investment programme with which Bayer AG intends to advance new technologies, automation and digitalization within its own Group.
This new production plant from Bayer is expected to contribute significantly to the pharmaceutical industry, focusing on the production of medicines for health-critical areas like ophthalmology and oncology. The advanced technologies used in this facility, including automation and robot-controlled systems, are revolutionizing the production of diseases-fighting pharmaceuticals, such as injection and infusion solutions.
Source: www.dpa.com
